Tirzepatide: 50mg (5mg*10vials/box)

Description

Usage: All products on this site are for In-Vitro Research, Development use only. Products are Not for Human consumption of any kind.

Data

Name: Tirzepatide

CAS No.: 2023788-19-2

PubChem CID: 156588324

IUPHAR/BPS: 11429

DrugBank: DB15171

ChemSpider: 76714503

UNII: OYN3CCI6QE

KEGG: D11360

ChEMBL: ChEMBL4297839

Formula: C225H348N48O68

Molar mass: 4813.527 g·mol−1

Other Names: LY3298176, GIP/GLP-1 RA

Purity: 98.5%min

Brand Name: UNEWLIFE

Grade: Pharm Medicine Grade

MFG: each batch fresh in 2023

Shelf Life: 2 years of proper storage

Appearance: White Powder

Test Reports: MS/COA/HPLC

Packing: 5mg*10vials/box

Label: without labels, can be OEM/ODM customized.

Box: white carton box, that can be OEM/ODM customized.

Shipping: by express or post.

Feedback: How do they say? More reviews here

For more questions, check the answers here: FAQ 

Description

Tirzepatide is a first-in-class medication that activates both the GLP-1 and GIP receptors, which leads to improved blood sugar control.
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are hormones involved in blood sugar control.

Tirzepatide is indicated to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise.

 

Mechanism of action

Tirzepatide is an analogue of gastric inhibitory polypeptide (GIP), a human hormone that stimulates the release of insulin from the pancreas. Tirzepatide is a linear polypeptide of 39 amino acids that has been chemically modified by lipidation to improve its uptake into cells and its stability to metabolism. It completed phase III trials globally in 2021.

Tirzepatide has a greater affinity to GIP receptors than to GLP-1 receptors, and this dual agonist behavior has been shown to produce greater reductions of hyperglycemia compared to a selective GLP-1 receptor agonist. Signaling studies have shown that this is due to tirzepatide mimicking the actions of natural GIP at the GIP receptor. However, at the GLP-1 receptor, tirzepatide shows bias towards cAMP (a messenger associated with regulation of glycogen, sugar and lipid metabolism) generation, rather than β-arrestin recruitment. This combination of preference towards GIP receptor and distinct signaling properties at GLP-1 suggest this biased agonism increases insulin secretion.
Tirzepatide has also been shown to increase levels of adiponectin, an adipokine involved in the regulation of both glucose and lipid metabolism, with a maximum increase of 26% from baseline after 26 weeks, at the 10 mg dosage.